Transaction #32462 · Form 4 · 0001610717-26-000434
IDEAYA Biosciences, Inc. · Exercise / conversion · Common Stock
IDEAYA Biosciences, Inc. · Transacted October 6, 2026 · Filed October 8, 2026
What does this filing report?
An SEC Form 4 filing for IDEAYA Biosciences, Inc. records an exercise / conversion involving Common Stock on October 6, 2026. The reported quantity was 26,338. The filing date is October 8, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- IDEAYA Biosciences, Inc.
- Company CIK
- 0001676725
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 26,338
- Reported price
- 4.31
- Reference value
- 113,516.78
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 717,033
- Ownership description
- Not reported
- SEC acceptance time
- Oct 8, 2026, 7:03 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Hata Yujiro S ↗
President and CEO · Director
CIK 0001649119
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date.
- F2
- This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3
- This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4
- The shares subject to the option are fully vested and exercisable.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.